Should we still focus that much on cardiovascular mortality in end stage renal disease patients? The CONvective TRAnsport STudy

PLoS One. 2013 Apr 19;8(4):e61155. doi: 10.1371/journal.pone.0061155. Print 2013.

Abstract

Background: We studied the distribution of causes of death in the CONTRAST cohort and compared the proportion of cardiovascular deaths with other populations to answer the question whether cardiovascular mortality is still the principal cause of death in end stage renal disease. In addition, we compared patients who died from the three most common death causes. Finally, we aimed to study factors related to dialysis withdrawal.

Methods: We used data from CONTRAST, a randomized controlled trial in 714 chronic hemodialysis patients comparing the effects of online hemodiafiltration versus low-flux hemodialysis. Causes of death were adjudicated. The distribution of causes of death was compared to that of the Dutch dialysis registry and of the Dutch general population.

Results: In CONTRAST, 231 patients died on treatment. 32% died from cardiovascular disease, 22% due to infection and 23% because of dialysis withdrawal. These proportions were similar to those in the Dutch dialysis registry and the proportional cardiovascular mortality was similar to that of the Dutch general population. cardiovascular death was more common in patients <60 years. Patients who withdrew were older, had more co-morbidity and a lower mental quality of life at baseline. Patients who withdrew had much co-morbidity. 46% died within 5 days after the last dialysis session.

Conclusions: Although the absolute risk of death is much higher, the proportion of cardiovascular deaths in a prevalent end stage renal disease population is similar to that of the general population. In older hemodialysis patients cardiovascular and non-cardiovascular death risk are equally important. Particularly the registration of dialysis withdrawal deserves attention. These findings may be partly limited to the Dutch population.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Distribution
  • Aged
  • Cardiovascular Diseases / complications*
  • Cardiovascular Diseases / mortality*
  • Cause of Death
  • Female
  • Follow-Up Studies
  • Humans
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / mortality*
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Registries / statistics & numerical data
  • Renal Dialysis / statistics & numerical data

Grants and funding

CONTRAST is financially supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland, grant C02.2019) and unrestricted grants from Fresenius Medical Care (The Netherlands) and Gambro Lundia AB (Sweden). Additional support was received from the Dr. E.E. Twiss Fund, Roche Netherlands; the International Society of Nephrology/Baxter Extramural Grant Program; the Dutch Organization for Health Research and Development (ZonMW, grant 17088.2802). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.